289 related articles for article (PubMed ID: 33920446)
1. AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery.
Halder AK; Cordeiro MNDS
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920446
[TBL] [Abstract][Full Text] [Related]
2. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
3. Multi-Target Chemometric Modelling, Fragment Analysis and Virtual Screening with ERK Inhibitors as Potential Anticancer Agents.
Halder AK; Giri AK; Cordeiro MNDS
Molecules; 2019 Oct; 24(21):. PubMed ID: 31671605
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling, virtual screening, and molecular docking studies for discovery of novel Akt2 inhibitors.
Fei J; Zhou L; Liu T; Tang XY
Int J Med Sci; 2013; 10(3):265-75. PubMed ID: 23372433
[TBL] [Abstract][Full Text] [Related]
5. Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor.
Al-Sha'er MA; Taha MO
J Mol Graph Model; 2018 Aug; 83():153-166. PubMed ID: 29456101
[TBL] [Abstract][Full Text] [Related]
6. In search of AKT kinase inhibitors as anticancer agents: structure-based design, docking, and molecular dynamics studies of 2,4,6-trisubstituted pyridines.
Trejo-Soto PJ; Hernández-Campos A; Romo-Mancillas A; Medina-Franco JL; Castillo R
J Biomol Struct Dyn; 2018 Feb; 36(2):423-442. PubMed ID: 28150530
[TBL] [Abstract][Full Text] [Related]
7. Multi-Target In Silico Prediction of Inhibitors for Mitogen-Activated Protein Kinase-Interacting Kinases.
Halder AK; Cordeiro MNDS
Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827668
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer.
Akhtar N; Jabeen I
Curr Cancer Drug Targets; 2018; 18(9):830-846. PubMed ID: 28669343
[TBL] [Abstract][Full Text] [Related]
9. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
Chaudhari P; Bari S
Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
[TBL] [Abstract][Full Text] [Related]
11. Structure-based pharmacophore models to probe anticancer activity of inhibitors of protein kinase B-beta (PKB β).
Akhtar N; Jabeen I; Jalal N; Antilla J
Chem Biol Drug Des; 2019 Mar; 93(3):325-336. PubMed ID: 30354009
[TBL] [Abstract][Full Text] [Related]
12. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Du-Cuny L; Song Z; Moses S; Powis G; Mash EA; Meuillet EJ; Zhang S
Bioorg Med Chem; 2009 Oct; 17(19):6983-92. PubMed ID: 19734051
[TBL] [Abstract][Full Text] [Related]
13. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
15. Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.
Mahajan P; Wadhwa B; Barik MR; Malik F; Nargotra A
Mol Divers; 2020 Feb; 24(1):45-60. PubMed ID: 30798436
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
17. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
18. Discovery of new JNK3 inhibitory chemotypes via QSAR-Guided selection of docking-based pharmacophores and comparison with other structure-based pharmacophore modeling methods.
Tuffaha GO; Hatmal MM; Taha MO
J Mol Graph Model; 2019 Sep; 91():30-51. PubMed ID: 31158642
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors.
Dong X; Zhou X; Jing H; Chen J; Liu T; Yang B; He Q; Hu Y
Eur J Med Chem; 2011 Dec; 46(12):5949-58. PubMed ID: 22027102
[TBL] [Abstract][Full Text] [Related]
20. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
